RUBIS: Half-Year Statement On Rubis' Liquidity Agreement With Exane BNP Paribas
Date
1/8/2025 12:01:33 PM
(MENAFN- GlobeNewsWire - Nasdaq) Paris, 8 January, 2025 – 5:45 pm
Pursuant to the liquidity agreement that Rubis has entered into with Exane BNP Paribas, the liquidity account presented the following balances as at the settlement date of 31 December 2024:
85,679 Rubis shares €259,101
The following trades were made in the second half of 2024:
183,912 securities were purchased for a total of €4,885,003 (1,146 transactions) 179,042 securities were sold for a total of €4,797,178 (1,414 transactions)
Reminder:
The previous half-year statement as of 30 June 2024 disclosed the following balances on the liquidity account: 81,253 Rubis shares €325,422
The following trades were made in the first half of 2024:
346,002 securities were purchased for a total of €10,218,263 (2,262 transactions) 329,474 securities were sold for a total of €9,730,520 (1,951 transactions)
The liquidity account presented the following balances as of 1st July 2021, the date of implementation of AMF decision No. 2021-01 of 22 June 2021:
51,976 Rubis shares €1,132,714
The liquidity account presented the following balances as of 31 December 2018, the date of implementation of AMF decision No. 2018-1 of 2 July 2018:
36,128 Rubis shares €1,487,705
This document is a translation of the original French document and is provided for information purposes only.
The original French version takes precedence over this translation
| | Contact |
| | RUBIS – Legal department |
| | Tel: +(33) 1 44 17 95 95 |
Attachment
RUBIS: Half-year statement on Rubis' liquidity agreement with Exane BNP Paribas
MENAFN08012025004107003653ID1109069334
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.